Upcoming Events
Log In
Pricing
Free Trial

Wk 4, Case 1 - Review

HIDE
PrevNext

0:04

So the first case was a, a guest case or just case.

0:08

Um, and it was biopsy proven.

0:10

So it's as usual for pet coming for staging.

0:14

Uh, so you know, the type,

0:16

but sometimes we get cases where, uh, there's a mass, um,

0:20

they know or they think it's malignant, sending it for, um,

0:24

further characterization and staging.

0:27

And we get the chance to, you know, pro brainstorm

0:31

and give the French shell.

0:33

And we usually have fun with these cases,

0:36

but this is not the, the case most

0:38

of the time, uh, as you know.

0:41

So, um, as we always say, I'm not gonna go

0:46

with my regular standard, uh, search,

0:49

but I never look my, at my cases like this.

0:52

I always go systematic. I always go the way I do it.

0:55

This is so important in the geology.

0:57

I cannot emphasize it enough.

1:00

You have to always follow your system.

1:02

All you will, you will miss a finding.

1:05

Uh, if you don't go systematic, uh, especially we in pet,

1:10

we have sometime a lot of times cases with so many findings

1:13

that lights up like a Christmas tree and you get excited

1:16

and you go after, oh, look at this.

1:18

Oh, look at that. Oh, look at this.

1:19

And then, um, the satisfaction of the search kicks in

1:25

and you feel, okay, I find

1:27

I found enough findings in this patient and you conclude

1:31

and then, um, you missed findings

1:33

and sometimes, uh, findings

1:34

that you missed are really, really important.

1:37

Uh, so, um, you have to go systematic.

1:40

But these sessions are sessions just

1:44

to show you the findings

1:45

and explain it and answer your questions.

1:47

So, um, I'm not going systematic in my, in these cases,

1:51

so I don't want to give you the wrong impression

1:52

that this is how I look at my case.

1:54

This is not how I look at my case, right?

1:57

So, um, this, there is here the primary lesion, an ex vedic

2:02

mass, which is typical for G it's usually, um,

2:05

solid or necrotic.

2:06

Um, not, that's not what I mean,

2:08

but they are usually mass arising from the stomach.

2:11

Um, hypermetabolic, a lot of times they are exo,

2:15

um, uh, masses.

2:18

And then, um, in this case, this is a really necrotic, um,

2:23

uh, mass as you see,

2:25

but the, the viable peripheral part

2:27

is really intensely hypermetabolic, right?

2:30

Uh, it's not scrolling easily, I dunno why.

2:34

Um, and that's it, right?

2:39

For it. Another finding you see in here is when you scroll

2:43

through the, okay, you have to look,

2:44

okay, this is a gastric mass.

2:46

So the, the next thing I look at,

2:48

I look carefully at not only the per aortic

2:51

or two cable, you know, lymph nodes in the al

2:54

that we will always look at.

2:55

I look carefully around the stomach, right?

2:58

Because this is regional for this area.

3:01

I look at also the gastro hepatic area here.

3:03

Is there a small lymph node that might be hypermetabolic

3:06

but maybe not intensely hyperbolic, maybe still small,

3:09

too tiny below bit resolution.

3:11

So it's really mildly avid, which would be significant.

3:14

So I zoom in, I look at bit only carefully,

3:17

but I also look at the fuse damage.

3:19

So I'm looking for a lymph node in this region here, right?

3:24

Very carefully. Is there something I might miss if I look

3:26

like, you know, superficially

3:28

and go over it, you have to look carefully

3:32

for these lymph nodes, right?

3:34

There's a lymph node that passed

3:35

but it didn't look suspicious.

3:36

There's no activity whatsoever, right?

3:40

So you go carefully around these areas.

3:43

So always depending on where is the cancer, you have you,

3:47

you do your first look, but then you go back

3:49

and look carefully at the regional lymph node for this area.

3:53

Make sure that you're not missing a lymph node, right?

3:57

And then in the pre aortic area, there is nothing,

4:00

there's nothing, the mis enteric nodes,

4:04

there's nothing suspicious.

4:06

Neither hypermetabolic

4:08

nor uh, anatomically right in the city.

4:11

'cause we read the city too. There's nothing there, right?

4:15

Then let's go back because

4:17

after I look at this, I look at the liver.

4:19

Now looking at the pit only you will notice first the

4:23

patient had her arms down,

4:25

which we usually like the arms up.

4:28

This causes a lot of problem to us, right?

4:31

As you see, this is a noisy liver.

4:33

There's a lot of, um, noise signal

4:36

to noise ratio is not good.

4:39

What this is causing, this is causing that.

4:41

You see all these flicks here, look, this, what is this?

4:44

Is this a lesion or this is just noise? I dunno.

4:49

'cause you go like this and there's many of them.

4:52

Am I, am I gonna call all these

4:54

the static disease in the liver?

4:56

I can't 'cause this can be simply just noise, nothing.

5:01

But when I blow up this, uh, me image

5:06

and scroll, some of them really stand out.

5:09

Like this one here, it stands out.

5:12

I can see it and appreciate it. I cannot ignore it.

5:15

So, so I mentioned it in the report.

5:18

I say there are few scattered, subtle focal, uh, FDG

5:24

activity or uptake through the liver, similar to,

5:29

uh, the level of the, you know, noise.

5:33

What, just where I'm attention followup exams.

5:36

I don't call it metastatic disease yet,

5:38

but I bring it to the attention.

5:41

So next time this patient will get a PET scan,

5:45

my colleague will see my, my command

5:48

and look at this area very well.

5:51

Hopefully next time the patient will bring the arm up

5:55

and either

5:56

This will go away because this was noise, nothing.

5:59

And next time my colleague will look and see nothing

6:01

and say, well, the usually like if I'm reading the next

6:05

scan, what I would say is that what I would say?

6:08

It's not that. We'll ignore it. Ignore it totally.

6:10

Even if I see it, I will still talk about it

6:11

because it was mentioned in the prior report.

6:14

So you have to address it in the the next report.

6:18

You have to say, well,

6:19

or this is my opinion at least I'm just presenting

6:22

to you my, um, professional opinion.

6:25

I would say the, the scattered FCI

6:28

of activity described in the previous report are not

6:31

appreciated in the current report, likely represented, um,

6:35

technical image noise or something like that.

6:37

An artifact or an artifact. And I move on.

6:40

So why are we, why am I doing this first?

6:43

Because I am telling who, like the referring physician that

6:48

I know that there were foci that were mentioned before.

6:53

Because simply you might, didn't you,

6:56

you might ignore the prior report.

6:58

You were busy, you had a busy list,

7:00

and you just didn't look at the prior scan

7:02

or the prior report and you looked at this, right?

7:05

If you don't mention it, most time, most

7:08

of the time people think you don't know about it, right?

7:12

People, you, you don't assume that if you don't mention it,

7:14

it means that it's not there.

7:17

Not necessarily. Maybe you don't know about it,

7:19

maybe you didn't know that they saw it,

7:21

so you didn't look for it.

7:22

So you have to mention it.

7:24

So you tell them, I know about it.

7:26

I saw the Briar report, I saw the briar, um,

7:29

you know, documentation of it.

7:31

I look for them, they are not there. They were our artifact.

7:35

Have a peace of mind. This is nothing. The liver is clean.

7:38

So this is my approach.

7:40

So anything that was mentioned in the previous report,

7:44

I address it in my report and tell them what was it, right?

7:47

It resolved.

7:49

And this means that it was an infection

7:52

or it was a, it doesn't have, doesn't mean it'll make it

7:55

to my impression even if it wasn't the impression last time,

7:58

because last time they were worried about it.

8:00

This time it's not in my impression,

8:02

but it's in the body of my report.

8:04

So if the re referring physician was worried about this foy

8:07

last time, this time in the follow

8:09

up, he's not gonna find it.

8:10

In my impression. He will dig in my report

8:13

and find that I talked about it in the liver, right?

8:16

This is my, um, opinion. Um, that's it.

8:20

I don't think there's anything else in the, in that patient

8:22

that worth incidental findings.

8:25

You have to talk about it of course

8:28

because we report everything with radiologist

8:31

and nothing else I think in this patient.

8:34

Um, worth discussing.

Report

Please note: Items with dashed lines (--) are information withheld as it is not relevant for you to arrive at the correct findings and impression for the report and/or it was withheld for privacy information. The items were left in to show you the typical information documented in a PET report.

Clinical Indication:
-- years old with biopsy proven gastric GIST receiving chemotherapy.

Technique:
Preparation: Last oral intake (except water) on --at --.
Diabetic: --.
Blood glucose at time of FDG administration: --- mg/dL.
Radiopharmaceutical: -- mCi of F-18 FDG administered IV at -- at --.
Incubation interval: -- minutes.
Oral contrast: --.
Positioning: --.
PET/CT scanner: ---.
PET/CT acquisition: Vertex-to-mid-thighs.
PET reconstruction method: ---
Standardized uptake value (SUV): Corrected for body weight only.
CT: Low-dose, non-breath-hold, without intravenous contrast.
TOTAL DLP (Dose Length Product): -- mGy cm.

Comparison/Correlation:
--

Findings:
Technical quality: Diagnostic.
Measurements: Unless otherwise specified, all SUVs refer to maximum value in the target (mSUV) and all CT linear measurements are performed on axial images.


Head and Neck:
No suspicious FDG avid lesions within the head and neck.
No suspicious FDG avid cervical lymphadenopathy.


Chest:
No suspicious FDG avid lesions within the chest.
No suspicious FDG avid lung nodules.
No suspicious FDG avid hilar or mediastinal lymphadenopathy.
No pleural effusion, pericardial effusion or pneumothorax.


Abdomen and Pelvis:
Exophytic intensely hypermetabolic necrotic gastric lesion measuring 74 mm with Maximum SUV 10.6.

Small sub-centimeter mildly hypermetabolic periportal lymph node, likely reactive.
Few subtle foci of FDG activity scattered throughout the liver just above the heterogeneous parenchymal uptake without definite corresponding lesions on the non-contrast CT images.
Multiple low-attenuation hepatic lesions, do not demonstrate focal FDG activity above liver parenchymal uptake level.

There is normal physiologic tracer activity in the spleen, pancreatic head, bilateral adrenal beds, collecting system of both kidneys, portions of ureters, urinary bladder and several segments of bowel.


Skeleton and Soft Tissues:
No suspicious FDG avid lesions within the soft tissues or osseous structures.
No aggressive lytic or sclerotic lesions.

Impression:
1. Exophytic intensely hypermetabolic necrotic gastric lesion, consistent with biopsy proven GIST.
2. No suspicious hypermetabolic or enlarged retroperitoneal adenopathy.
3. Few subtle foci of FDG activity scattered throughout the liver just above the heterogeneous parenchymal uptake without definite corresponding lesions on the non-contrast CT images. Further assessment with liver-protocol MRI recommended.
4. No convincing evidence of other sites of hypermetabolic distant metastatic disease.

Case Discussion

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

PET/CT FDG

PET

Nuclear Medicine

CT

Bone & Soft Tissues